ELI LILLY AND COMPANY Finite-Lived Intangible Assets, Weighted-Average Useful Life (Deprecated 2012-01-31)
ELI LILLY AND COMPANY (LLY) reported Finite-Lived Intangible Assets, Weighted-Average Useful Life (Deprecated 2012-01-31) of 9 years for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-24.
Discontinued › Income Statement › Earnings Per Share
us-gaap:FiniteLivedIntangibleAssetsWeightedAverageUsefulLife · last filed 2012-02-24
- ELI LILLY AND COMPANY finite-lived intangible assets, weighted-average useful life (deprecated 2012-01-31) for fiscal 2010 was 900.00%.
pure
| Period end | Finite-Lived Intangible Assets, Weighted-Average Useful Life (Deprecated 2012-01-31) 12 month |
|---|---|
| 2010-12-31 | 900.00% 10-K · filed 2011-02-22 |
years
| Period end | Finite-Lived Intangible Assets, Weighted-Average Useful Life (Deprecated 2012-01-31) 12 month |
|---|---|
| 2011-12-31 | 9.00 years 10-K · filed 2012-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |